Trial Profile
A retrospective study to evaluate the effect of VEGFR1 single nucleotide polymorphism (SNP) in metastatic renal cell cancer (mRCC) patients treated with sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Sep 2015 New trial record